The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages

  Liu, Ruixin ^a   Liu, Dingxie ^a   Trink, Eliana ^a   Bojdani, Ermal ^a   Ning, Guang ^a,b   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MK 2206; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENOTYPE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; SUBSTRATE SPECIFICITY; THYROID NEOPLASMS;

MAMMALIA;

EID: 79953852883     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2644     Document Type: Article

References (40)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
2. ColonnaM,Guizard AV, Schvartz C, VeltenM,Raverdy N, Molinie F, Delafosse P, Franc B, Grosclaude P 2007 A time trend analysis of papillary and follicular cancers as a function of tumour size: A study of data from six cancer registries in France (1983-2000). Eur J Cancer 43:891-900 (Pubitemid 46366691)
3. Altekruse SF,KosaryCL,KrapchoM,NeymanN,AminouR,Waldron W,Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, LewisDR,Cronin K,ChenHS,Feuer EJ, StinchcombDG,EdwardsBK (eds) 2010 SEER Cancer Statistics Review, 1975-2007. (http://seer. cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site) Bethesda, MD: National Cancer Institute
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83: 2638-2648 (Pubitemid 29019586)
5. Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Fernandes JK 2007 Anaplastic thyroid carcinoma: An overview. Curr Oncol Rep 9:152-158 (Pubitemid 46332389)
6. Smallridge RC, Copland JA 2010 Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22:486-497
7. XingM2009 Identifying genetic alterations in poorly differentiated thyroid cancer: A rewarding pursuit. J Clin Endocrinol Metab 94: 4661-4664
8. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501 (Pubitemid 37328931)
9. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-BarónM2004 PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204
10. Paes JE, RingelMD2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387, viii-ix (Pubitemid 351698084)
11. Xing M 2010 Genetic alterations in the phosphatidylinositol-3 kinase/ Akt pathway in thyroid cancer. Thyroid 20:697-706
12. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J 1994 Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532 (Pubitemid 24264918)
13. Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, Park KC, Park SH, Hwang JH, Jo KW, ShongM2005 Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19:2748-2759 (Pubitemid 41577247)
14. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW 1998 Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39 (Pubitemid 28458022)
15. Di Cristofano A, Pandolfi PP 2000 The multiple roles of PTEN in tumor suppression. Cell 100:387-390
16. Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A 2008 Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res 68:444-449 (Pubitemid 351380070)
17. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS 2009 mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg 6:47-55
18. Hay N, Sonenberg N 2004 Upstream and downstream of mTOR. Genes Dev 18:1926-1945 (Pubitemid 39071573)
19. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508 (Pubitemid 43259931)
20. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ 2007 Rapamycin induces feedback activation of Akt signaling through an IGF-1Rdependent mechanism. Oncogene 26:1932-1940 (Pubitemid 46474636)
21. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, XingM2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116
22. Furuya F, Lu C, Willingham MC, Cheng SY 2007 Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28:2451-2458 (Pubitemid 350238946)
23. Liu D, XingM2008 Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-κB pathways. Thyroid 18:853-864
24. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW 2009 Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94:4107-4112
25. Liu D, Hou P, Liu Z, Wu G, XingM2009 Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311-7319
26. Papewalis C, Wuttke M, Schinner S, Willenberg HS, Baran AM, Scherbaum WA, SchottM2009 Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res 41:752-756
27. Liu D, Xing J, Trink B, Xing M 2010 BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127:2965-2973
28. Welkos S, O'Brien A 1994 Determination of median lethal and infectious doses in animal model systems. Methods Enzymol 235: 29-39
29. Chou TC, Talalay P 1983 Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 4:450-454
30. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH 2005 CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Cancer 104:1045-1048 (Pubitemid 41170233)
31. Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K, Dancey JE, Grever MR 2009 Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 33:1475-1480
32. Tolcher AW, Yap TA, Fearen I, Taylor A, Carpenter C, Brunetto AT, Beeram M, Papadopoulos K, Yan L, de Bono J, A phase I study of MK-2206,anoral potent allostericAktinhibitor (Akti), in patients (pts) with advanced solid tumor. Proc Annual Meeting of American Society of Clinical Oncology, Orlando, FL, 2009 (Abstract 3503)
33. Bader AG, Kang S, Zhao L, Vogt PK 2005 Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5:921-929 (Pubitemid 41766781)
34. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK 2003 Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093-1103
35. LindsleyCW2010 The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation: A 2009 update. Curr Top Med Chem 10:458-477
36. Xing M 2009 Genetic-targeted therapy of thyroid cancer: A real promise. Thyroid 19:805-809
37. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML 2004 Randomized phase II study of multiple dose levels of CCI-779, a novelmammaliantarget of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918 (Pubitemid 41103603)
38. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, EiermannW,Hess D,MorantR, Semiglazov V, BornerM,SalzbergM, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, CincottaM, MooreL2005PhaseIIstudyof temsirolimus(CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322 (Pubitemid 46206985)
39. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, RajeN2010 Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9:963-975
40. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM 2010 Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115:559-569